Log in
Enquire now
‌

US Patent 8455622 Variant target binding agents and uses thereof

Patent 8455622 was granted and assigned to Seagen on June, 2013 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Seagen
Seagen
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
8455622
Date of Patent
June 4, 2013
Patent Application Number
12516914
Date Filed
December 1, 2007
Patent Citations Received
‌
US Patent 12071476 IL-6 antibodies and fusion constructs and conjugates thereof
0
‌
US Patent 12016842 Methods of using anti-CD79b immunoconjugates
0
0
0
‌
US Patent 11712468 CD70 combination therapy
0
‌
US Patent 11759527 Anti-EGFR antibody-drug conjugates
‌
US Patent 11767365 BCMA antibodies and use of same to treat cancer and immunological disorders
‌
US Patent 11866496 Humanized anti-CD79B antibodies and immunoconjugates and methods of use
0
...
Patent Primary Examiner
‌
Chun Dahle
Patent abstract

The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8455622 Variant target binding agents and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.